Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT05759637
Recruiting Observational

Type 2 Diabetes, Obesity and Cortisol Excess

NCT05759637 · tracked via the Priya Life Science Italy tracker
Sponsor
Istituto Auxologico Italiano
Phase
Observational
Started
2022-05-06
Last updated
2025-03-24

Condition(s) studied

Diabetes Mellitus, Type 2ObesityCortisol; Hypersecretion

Investigational drug(s) / intervention(s)

1mg DST

1mg DST: measurement of cortisol levels after 1 mg of dexamethasone (DST) at 11 pm

Study summary

The present observational cross-sectional study is aimed to assess: the hidden hypercortisolism (HidHyCo) prevalence in a sample of Type 2 diabetes (T2D) patients and the clinical characteristics more frequently associated with the HidHyCo presence and the HidHyCo prevalence in an adequate sample of obese patients without T2D and the clinical characteristics more frequently associated with the HidHyCo presence.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: patients with T2D and Obesity Exclusion Criteria: * pregnancy/breast feeding, * sleep apnea, * prepuberal onset of hypertension, hormonal hypersecreting adrenal mass, * symptoms of hypercortisolism; * already known secondary hypertension; * conditions associated with increased hypothalamic-pituitary-adrenal (HPA) axis activity, -severe autoimmune/rheumatologic and hematologic diseases, alcoholism, kidney disease (glomerular filtration rate \<60) * drugs influencing the HPA axis activity. For inclusion in Group 2 the presence of T2D will be an exclusion criteria

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
Istituto Auxologico Italiano Milan Italy Recruiting
Niguarda Hospital Milan Italy Recruiting
Campus Bio-Medico University Roma Italy Recruiting
University of Siena Siena Italy Recruiting
Azienda Ospedaliero Universitaria, Santa Maria della Misericordia di Udine Udine Italy Recruiting

More Istituto Auxologico Italiano trials in Italy

Gait and Balance Impairment in Rare and Very Rare Neurological Diseases Recruiting
LONgitudinal and Integrated Evaluation of Biomarkers in reLation to phenotYpe in ALS Recruiting
Global Approach to Faint and Falls Recruiting
The FUnctional TricUspid REgurgitation by 3D EChocardiography Cooperative Study Recruiting
Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional Study Recruiting

Other trials for the same condition

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain Recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity Recruiting
Perception of Quality of Life in Patients Undergoing Endoscopic Vertical Gastroplasty Recruiting
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS) Starting soon
Susceptibility to Infectious Diseases in Obesity Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05759637 on ClinicalTrials.gov ↗ ← All trials in Italy